FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to							
Section 16. Form 4 or Form 5							
obligations may continue. See							
Instruction 1(b).							

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name <b>and</b> Ticker or Trading Symbol VTv Therapeutics Inc. [VTVT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
KINDLER JEFFREY B						<u>rncrapt</u>	<u>uu</u>	. <u>3 111C.</u> [ V	1 4 1 ]				X Directo	or		10% Ow	ner		
(Last) (First) (Middle)					Date of Earliest Transaction (Month/Day/Year)								X Officer (give title below)			Other (specify below)			
C/O VTV THERAPEUTICS INC.						03/10/2017								Executive Chairman					
4170 MENDENHALL OAKS PKWY																			
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)													Line)  X Form filed by One Reporting Person						
HIGH POINT NC 27265												Form filed by More than One Reporting							
(City) (State) (Zip)													Person						
(City)	(5	iale)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,			, Transaction Disposed Code (Instr. 5)			ties Acquired (A) o d Of (D) (Instr. 3, 4 a		Beneficia Owned F	s ally following (	6. Owne Form: D D) or Ir I) (Instr	Direct of direct E	7. Nature of Indirect Beneficial Ownership		
								Code V	Amou	nt	(A) or (D)	Price	Reported Transact (Instr. 3 a	tion(s)		(	Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
(e.g., puts, calls, warrants, options, convertible securities)															1				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Coc	nsaction le (Instr			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	O F-I D OI (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Cod	le V	(A)	(D)	Date Exercisable	Expiration Date		Title	Amount or Number of Shares							
Restricted Stock Unit	(1)	03/10/2017		A		35,000		(2)	03/10/20	20	Class A Common Stock	35,000	\$0.00	35,000		D			

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A common stock.
- 2. Grant vests in three equal annual installments beginning on March 10, 2018.

## Remarks:

/s/ Stephen L. Holcombe, Attorney-in-Fact

03/14/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.